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Background Obesity is a significant risk factor for psoriasis and body mass index
(BMI) correlates with disease severity.
Objectives To investigate the relationship between obesity and psoriasis, focusing
on the role of adipokines such as leptin and resistin.
Patients ⁄methods Patients with psoriasis (n = 30) were recruited and their BMI,
waist circumference and disease severity [Psoriasis Area and Severity Index
(PASI)] were recorded. Fasting serum samples were obtained on enrolment and
after a course of ultraviolet (UV) B treatment. Age-, sex- and BMI-matched
healthy controls were also recruited.
Results On enrolment, serum leptin and soluble leptin receptor levels were not
raised compared with the controls. However, resistin, interleukin (IL)-1b, IL-6,
and chemokines CCL2, CXCL8 and CXCL9 were all significantly elevated in the
patient group and serum resistin correlated with disease severity (r = 0Æ372,
P = 0Æ043). Improvement after UVB treatment was accompanied by decreased
serum CXCL8. In vitro, both leptin and resistin could induce CXCL8 and tumour
necrosis factor-a production by blood monocytes, and leptin could additionally
induce IL-1b and IL-1 receptor antagonist production. Leptin also dose depen-
dently increased secretion of the growth factor amphiregulin by ex vivo-cultured
lesional psoriasis skin.
Conclusions These data support the view that leptin and resistin may be involved in
the pathogenesis of psoriasis in overweight individuals, possibly by augmenting
the cytokine expression by the inflammatory infiltrate.
Psoriasis is a common inflammatory T-cell-mediated skin dis-
order, affecting 2–3% of the population,1 in which the most
prominent microscopic abnormality is hyperproliferation and
altered differentiation of keratinocytes. While the disease has
several distinct yet overlapping phenotypes,2 by far the most
common is chronic plaque psoriasis, which affects about 90%
of patients. The aetiology of psoriasis is unknown but the dis-
ease is believed to have an autoimmune basis and a strong
genetic component.3 Several HLA alleles are associated with
psoriasis, in particular HLA-Cw*0602, which is probably the
major genetic determinant of the disease.4 Despite strong
hereditary factors exogenous stimuli such as infection, trauma
and stress play an important role in disease manifestation.5–8
Obesity has long been associated with and considered detri-
mental for psoriasis. Henseler and Christophers9 reported in
1995 that a substantial proportion of psoriasis patients hospi-
talized for treatment were obese. Patients weighing more than
their ideal bodyweight also tend to have worse psoriasis in
terms of the proportion of involved skin,10 and the extent of
their psoriasis lesions correlates with body mass index
(BMI).11 In a recent case–control study, Naldi et al.8 found that
a moderately increased BMI (26–29) was associated with a
slightly increased risk of psoriasis, and clinical obesity
(BMI > 29) more than doubled the risk of psoriasis. Further
support for a link between these two conditions comes from
the observation that obesity is more prevalent in patients with
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severe as opposed to mild psoriasis12 and an increased preva-
lence of metabolic syndrome in psoriasis patients has recently
been reported.13 Reports also exist of a favourable outcome
after 4 weeks on a low-energy (855 kcal daily) diet14 or reso-
lution of psoriasis after gastric bypass surgery,15 but such
treatment modalities require closer examination and controlled
trials. Thus, a causal relationship between obesity and psoriasis
has not been fully established as obesity may occur as a conse-
quence of developing psoriasis,16 although the obese state
may well exacerbate the severity of the disease or derive from
a common underlying pathophysiology.17
White adipose tissue is composed of mature triglyceride-
filled adipocytes, along with preadipocytes, endothelial cells,
fibroblasts and leucocytes.18 Expansion of adipose tissue dur-
ing weight gain leads to the recruitment of macrophages into
the adipose tissue19 and this is probably mediated by adipo-
cyte-derived chemokines such as CCL2 (monocyte chemo-
attractant protein-1).20 Macrophages are the chief source of
adipose tissue-derived tumour necrosis factor (TNF)-a21 and
are an important component of the nonadipocyte fraction of
this tissue, which is also the main source of interleukin (IL)-6
and CXCL8.22 These cytokines are abundant in psoriasis skin,23
their levels in suction blister fluids of involved psoriasis skin
correlate with disease severity24 and both have established
roles in psoriasis pathogenesis.25
Leptin is one of the main adipose-derived cytokines and has
been investigated primarily for its role in controlling energy
homeostasis by regulating appetite.26,27 Leptin is also impor-
tant for cell-mediated immunity and CD4+ T cells are hypore-
active in leptin-deficient mice.28 Congenital leptin deficiency
in humans results in lower frequency of blood CD4+ T cells
as well as impaired T-cell proliferation and production of
cytokines such as interferon (IFN)-c,29 and this hyporespon-
siveness can be restored by exogenous leptin.30 Patients suffer-
ing from common variable immunodeficiency have lower
serum leptin levels than healthy individuals; however, admin-
istration of exogenous leptin could not reverse this defi-
ciency.31,32 Leptin appears to contribute to T helper (Th) 1
and suppresses Th2 immune responses. In vitro, leptin acts on
naive T cells, increasing their IL-2 secretion and proliferation,
as well as increasing IFN-c production by memory T cells.28
Leptin is required for the induction and progression of auto-
immune encephalomyelitis in mice,33 and it was recently
shown that leptin inhibits the proliferation of CD4+FoxP3+
regulatory T cells.34 Thus, elevated leptin levels may lead to
enhanced Th1 type immune responses due to diminished
regulatory T cell activity. Leptin also increases macrophage
activity and their production of IL-1b, IL-6, TNF-a and
IL-12.35,36 Additionally, leptin can alter the morphology of
monocyte-derived dendritic cells and increase their production
of IL-1b, IL-6, TNF-a and IL-12p70, and priming of naive
T cells by leptin-treated dendritic cells resulted in increased
Th1 polarization.37
Resistin was originally discovered in mouse adipocytes and
assigned a key role in the induction of murine insulin resis-
tance.38 Human adipocytes however do not produce resistin,39
but resistin is expressed by cells in the stromal compartment
of adipose tissue,21 particularly macrophages.19 Resistin mRNA
is increased in the subcutaneous adipose tissue of obese com-
pared with lean individuals,40 but there is only a very weak
correlation between BMI and serum resistin levels41 although
the proportion of mononuclear leucocytes within adipose
tissue correlates well with BMI.19 Resistin is also expressed by
peripheral blood mononuclear cells (PBMC),42,43 particularly
by monocytes44,45 and is upregulated during their differentia-
tion into macrophages.44,45 Lipopolysaccharides (LPS) and the
inflammatory cytokines IL-1b, IL-6 and TNF-a have all been
demonstrated to induce resistin mRNA expression by human
PBMCs,42 and elevated levels of resistin can be induced in the
blood of healthy individuals in response to exogenous LPS.45
Resistin dose dependently stimulates its own production
(autocrine effect) and stimulates TNF-a, IL-1b, IL-6 and
CXCL8 in PBMCs43 as well as IL-12 in macrophages.46 The
autocrine effect of resistin and its ability to induce other pro-
inflammatory cytokines that in turn can stimulate more resi-
stin synthesis, suggests a vicious cycle type pathogenic role for
resistin.
Although numerous clinical studies have suggested that
obesity has an adverse effect on psoriasis,8–13,16 information is
lacking about potential pathophysiological pathways that may
be responsible for this association. Here we examine serum
adipokine and cytokine levels of patients before and after a
course of narrowband 310 nm ultraviolet B (NB-UVB) treat-
ment and compare with BMI-matched nonpsoriatic controls.
Further, we investigate how either local or systemic increases
in leptin or resistin might trigger or exacerbate psoriasis.
Materials and methods
Recruitment and clinical evaluation of patients
and controls
Thirty patients with chronic plaque psoriasis and 29 age-, sex-
and BMI-matched controls were recruited to the study. None
of the patients were on systemic treatment. On recruitment,
weight, height and waist circumference of all individuals in
the study were recorded. Disease severity was assessed before
and after treatment with the Psoriasis Area and Severity Index
(PASI)47 by the same physician (J.T.S.). All patients completed
a questionnaire involving past treatment (medication or visits
to the Blue Lagoon) and whether they had noticed a change
in their condition after losing or gaining weight. Patients
underwent treatment in the Blue Lagoon Dermatological
Clinic, which involves regular bathing in the lagoon water
combined with NB-UVB irradiation. On completion of treat-
ment, the PASI score, weight and waist measurements were
again recorded and a second fasting serum sample taken. All
participants gave their informed consent before enrolment.
The National Bioethics Committee of Iceland and the Icelandic
Data Protection Authority approved the study. A further 16
patients with chronic plaque psoriasis and three healthy con-
trol volunteers were recruited for skin biopsy for ex vivo skin
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culture and immunohistochemistry. Informed consent was
obtained from all subjects, under protocols approved by the
Institutional Review Board of the University of Michigan.
Measurement of cytokines, adipokines and leptin
receptor in serum
Blood was collected from patients and controls after an over-
night fast. Serum was isolated after clotting and stored in
aliquots at )70 C until used. Leptin, soluble leptin receptor,
adiponectin, resistin, CXCL8 and IL-22 were determined by
enzyme-linked immunosorbent assay (ELISA) (R&D Systems,
Oxford, U.K.). The cytokines IL-1b, IL-6, IL-10, IL-12p70,
CCL2 and CXCL9 were measured using a microsphere-based
multiplexed immunoassay (Bio-Plex; Bio-Rad, Sundbyberg,
Sweden).
Monocyte cytokine production in stimulated whole blood
Sodium heparin-treated whole blood was collected from
healthy volunteers and incubated for 16 h with recombinant
human resistin (Santa Cruz Biotechnology, Heidelberg,
Germany) or recombinant human leptin (Santa Cruz Biotech-
nology) in the presence of 10 lg mL)1 brefeldin A (Sigma-
Aldrich, St. Louis, MO, USA). Cells were first stained for
surface CD14 expression (PerCP-CD14, clone M/P9; BD Bio-
sciences, San Jose, CA, USA), then erythrocytes were lysed
(FACS lysing solution, BD Biosciences), lymphocytes fixed and
permeabilized (FACS permeabilizing solution; BD Biosciences),
and stained intracellularly with fluorescein-isothyocyanate-,
phycoerythrin- or allophycocyanin-labelled monoclonal anti-
bodies against IL-1 receptor antagonist (IL-1ra; clone AS17),
IL-1b (AS10), CXCL8 (AS14) and TNF-a (6401.1111; BD Bio-
sciences). After washing, cells were analysed using a FACS-
calibur flow cytometer and Cell Quest Pro software (BD
Biosciences).
Ex vivo skin culture
Three psoriatic and three control donors each gave eight
2-mm punch skin biopsies. The biopsies were treated with
different concentrations of recombinant leptin (R&D Systems,
Minneapolis, MN, U.S.A.) for a total of 5 days in M154 med-
ium (Cascade Biologics, Portland, OR, U.S.A.) when the tissue
supernatants were harvested and stored at )70 C. Amphireg-
ulin was quantified using an ELISA (R&D Systems) according
to the manufacturer’s instructions. Recombinant human
amphiregulin (R&D Systems) was used as the standard, and
the blank was unexposed culture medium.
Immunohistochemical staining and automated analysis
Immunohistochemistry was performed with antileptin receptor
antibody (R&D Systems) according to the manufacturer’s
instructions and visualized with 3-amino-9-ethyl-carbazole
(BioGenex, San Ramon, CA, U.S.A.), followed by haematoxy-
lin counterstain (Biocare Medical, Concord, CA, U.S.A.).
Stained sections were examined by light microscopy, and each
stained tissue section was subjected to image capture in its
entirety via five digital images taken through the 20 · objec-
tive. All images were then analysed using Image Pro software
(Image-Pro Plus; Media Cybernetics, Silver Spring, MD,
U.S.A.), to capture the area of positive staining for leptin re-
ceptor in epidermis vs. dermis. Statistical analysis was per-
formed using a two-tailed unpaired t-test assuming equal
variances; P values £ 0Æ05 were considered to be significant.
Real-time quantitative polymerase chain reaction
Leptin and leptin receptor expression were validated by quan-
titative real-time reverse transcriptase-polymerase chain reac-
tion (qRT-PCR). Primers for leptin (cat. no. PPH00581E),
leptin receptor (cat. no. PPH00028B) and the housekeeping
gene RPLP0 (36B4, cat. no. PPH21138E) were obtained from
Superarray Biosciences (Frederick, MD, U.S.A.). The reverse
transcription reaction was performed on 0Æ5 lg of RNA tem-
plate and cDNA was synthesized using anchored-oligo (dT)18
primers as instructed by the manufacturer (Roche Diagnostics,
Mannheim, Germany). qRT-PCR was carried out on the Light-
Cycler 2.0 system (Roche Diagnostics). LightCycler FastStart
DNA MasterPLUS SYBR Green I was used for all PCR reactions
as instructed by the manufacturer. The reaction profile con-
sisted of an initial denaturation at 95 C for 15 min followed
by 40 cycles of PCR at 95 C for 10 s (denaturation), 58 C
for 10 s (annealing) and 72 C for 10 s (extension). The fluo-
rescence emitted was captured at the end of the extension step
of each cycle at 530 nm. Results were normalized to the
expression of the housekeeping gene 18S ribosomal RNA.
Statistical analyses
Data sets were tested for normality using the Kolmogorov–
Smirnov test, and statistical significance determined by
Student’s t-test, paired t-test (pre- and post-treatment) or
Mann–Whitney rank sum tests where appropriate using Sigma
Plot version 10 for windows (Systat, Erkrath, Germany.) Data
series were also tested for significance with a one-way ANOVA
with Dunnett’s post-test using GraphPad Prism version 4 for
Windows (GraphPad Software, San Diego, CA, U.S.A.).
Results
The study groups
The treatment group comprised 30 patients with chronic pla-
que psoriasis (14 women and 16 men) and 29 age-, sex- and
BMI-matched volunteers (16 women and 13 men) with no
skin disease. As shown in Table 1, the patients and controls
were very similar regarding age, weight, waist circumference,
BMI, fasting serum triglycerides, cholesterol or high-density
lipoproteins. The weight and waist circumference of the
patients did not change during the treatment. The patients
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responded to a questionnaire. While the majority of the
patients had not noticed any marked changes in their body
weight after the onset of psoriasis, six (20%, two women and
four men) reported improvement in their disease following
weight loss. Four reported that scaling and erythema lessened
after weight loss and worsened following weight gain and the
remaining two patients reported that scaling and erythema
was decreased following weight loss.
Disease severity
The patients’ disease severity was evaluated before and after
the treatment using the PASI score. The mean score was 15Æ33
on enrolment (range 4Æ9–34Æ8). As expected, a dramatic
decrease in disease severity (PASI) was recorded after the UVB
and bathing treatment (mean PASI 3Æ84, P < 0Æ001).
BMI and waist circumference correlate with serum leptin
The patients and matched controls enrolled in this study had a
mean BMI of 30Æ5 and 30Æ8 kg m)2, respectively. Among men
in the control group, there was a strong positive correlation
between serum leptin and BMI (r = 0Æ87, P < 0Æ001), but this
was not the case for the female controls (r = 0Æ26, not signifi-
cant). Interestingly, both male and female patients with psoriasis
demonstrated a correlation between BMI and leptin (r = 0Æ65,
P = 0Æ012 for women and r = 0Æ59, P = 0Æ016 for men). A
very similar relationship existed between waist circumference
Table 1 Characteristics of the patient and control study groups. Mean
values for each measurement are shown together with minimum and
maximum values
Controls Patients
Age (years) 47Æ14 52Æ87
22–83 24–77
Height (m) 1Æ67 1Æ73
1Æ52–1Æ83 1Æ54–1Æ88
Weight (kg) 86Æ05 90Æ54
59Æ6–143 58Æ7–125
Waist circumference (cm) 105Æ61 105Æ00
73Æ6–149 77–129
BMI (kg m)2) 30Æ81 30Æ51
22Æ0–49Æ5 18Æ8–39Æ4
Triglycerides (mmol L)1) 1Æ32 1Æ57
0Æ6–4Æ6 0Æ5–4Æ8






BMI, body mass index.
Fig 1. (a–f) Adipokine levels in serum from
patients and matched controls. Adipokines
were measured by enzyme-linked
immunosorbent assay in the serum of patients
with psoriasis (Pat) and healthy body mass
index-, age- and sex-matched controls (Con)
after overnight fast. Leptin, soluble leptin
receptor and adiponectin were found not to
be elevated in patients compared with
matched controls (a–e). Resistin, however,
was significantly increased (f). Boxes
represent median and interquartile range,
whiskers indicate the 10th and 90th
percentiles, with values outside this range
plotted individually; numbers within boxes
indicate the number of individuals tested.
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and serum leptin in both groups. There was a weak correlation
between BMI and disease severity among the men (r = 0Æ32)
but this was not statistically significant and no correlation
between the two variables was seen among the women.
Leptin is not elevated in the blood of patients
with psoriasis
There were no significant differences in the serum concentra-
tions of leptin, soluble leptin receptor or adiponectin between
patients and controls (Fig. 1a–e). As expected, women in both
the patient and control groups had significantly higher serum
leptin levels than the men (P = 0Æ017). However, patients’
leptin levels were not significantly different from those of the
BMI-matched nonpsoriasis controls for either sex (Fig. 1a,b).
Serum leptin levels did not correlate with disease severity in
either male or female patients.
Serum resistin is elevated in psoriasis and correlated
with disease severity
The patients had significantly more resistin in their serum than
did the controls (P < 0Æ001, Fig. 1f) and this correlated with
their disease severity (r = 0Æ372, P = 0Æ043, Fig. 2).
Serum cytokine levels are altered in psoriasis patients,
and responded to NB-UVB therapy
IL-1b, IL-6, CCL2, CXCL8 and CXCL9 were all significantly
elevated in the pretreatment serum of the patients compared
Fig 2. Disease severity (Psoriasis Area and Severity Index, PASI)
correlates with patients’ serum resistin concentration (n = 30,
r = 0Æ372, P = 0Æ043). Dashed lines indicate 95% confidence intervals.
Fig 3. (a–f) Cytokine levels in serum from
patients (Pat) and controls (Con). Cytokines
were measured in fasting serum by multiplex
assay or enzyme-linked immunosorbent assay.
Interleukin (IL)-1b, IL-6, CCL2 (MCP-1),
CXCL8 (IL-8) and CXCL9 (MIG) were all
significantly elevated in patients compared
with matched healthy controls. Boxes and
whiskers are described in Figure 1.
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with the controls (Fig. 3); however, no difference was seen in
levels of IL-22 (Fig. 3c). Serum IL-10 and IL-12p70 were also
increased in the patients (data not shown). Following the
treatment, a significant decrease was seen in the serum con-
centration of both CXCL8 (P = 0Æ001) and IL-22 (P < 0Æ001),
but no significant changes were observed in serum for IL-1b
or IL-6 (data not shown). Although some decrease was
observed in resistin levels after treatment this was not signifi-
cant (P = 0Æ1).
Leptin and resistin induce proinflammatory cytokine
production by monocytes
As serum leptin correlated with the BMI of patients with pso-
riasis and serum resistin correlated with their disease severity,
we chose to examine the effects of leptin and resistin on
cytokine production by blood monocytes ex vivo using intra-
cellular cytokine staining and flow cytometry. The cytokine
content of monocytes after 16 h of incubation with recombi-
nant leptin or resistin is shown in Figure 4. Both leptin
and resistin could induce significant amounts of CXCL8 and
TNF-a production by the monocytes. In addition, leptin was
able to induce the accumulation of IL-1b and IL-1ra in
monocytes (Fig. 4c,d).
Leptin-induced amphiregulin expression by in vitro
cultured skin
As the direct effects of leptin on skin are currently unknown, we
exposed biopsies from healthy and plaque psoriasis skin to lep-
tin in vitro. Addition of exogenous leptin led to a dose-dependent
accumulation of the epidermal growth factor (EGF)-like growth
factor amphiregulin in the medium from cultured psoriasis skin,
but an increase in amphiregulin was not observed when non-
psoriatic control skin was cultured (Fig. 5).
Enhanced expression of leptin receptor was seen
in uninvolved psoriasis skin, but was downregulated
in lesional epidermis
Because psoriasis skin, but not healthy skin, responded to the
addition of exogenous leptin by producing the growth factor
amphiregulin, we investigated whether this difference was
due to variations in leptin receptor expression. First we exam-
ined the leptin and leptin receptor mRNA expression in
healthy as well as symptom-free and lesional psoriasis skin
Fig 4. Exogenous leptin (a–d) and resistin (e–h) induce blood monocytes from healthy volunteers to produce proinflammatory cytokines ex vivo in
a dose-dependent manner. Plots show proportion of cytokine+ CD14+ monocytes detected by intracellular cytokine staining and flow cytometry
(mean ± SD). Statistical significance indicated as *P < 0Æ05, **P < 0Æ01, by one-way ANOVA with Dunnett’s test. TNF, tumour necrosis factor;
IL, interleukin; IL-1ra, IL-1 receptor antagonist.
Fig 5. Exogenous leptin induces in vitro cultured psoriasis skin to
express the growth factor amphiregulin in a dose-dependent manner.
Open squares, control skin; filled squares, psoriasis skin, mean
(n = 3) ± SD, *P < 0Æ05, one-tailed t-test.
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using qRT-PCR (Fig. 6). All three skin phenotypes contained
similar amounts of leptin mRNA (Fig. 6a). Lesional psoriasis
skin, however, contained significantly (P < 0Æ005) less mRNA
for leptin receptor than either healthy or symptom-free psoria-
sis skin (Fig. 6b) and this observation was supported immu-
nohistochemically (Fig. 7). Thus, lesional psoriasis epidermis
(Fig. 7c) expressed less leptin receptor than either healthy
(Fig. 7a) or uninvolved psoriatic epidermis (Fig. 7b) and this
finding was confirmed using computer-assisted image quanti-
fication (Fig. 7d). Interestingly, the converse was seen in the
dermal compartment, where very little leptin receptor staining
was seen in healthy or clinically uninvolved dermis, but some
cells within the lesional dermis stained strongly for leptin
receptors (Fig. 7c,h).
Discussion
In this study we show that serum resistin is elevated in
patients with psoriasis compared with age-, sex- and BMI-
matched healthy controls and that resistin correlates with dis-
ease severity. This finding confirms a small prospective study
assessing the effects of treatment with the oral retinoid acitre-
tin48 in which increased resistin levels were measured in the
blood of patients with psoriasis and compared with age-, sex-
and BMI-matched controls; however, that study did not report
any correlation between disease severity and serum resistin,
probably because only 10 patients were enrolled. However,
we and recently others49 have now shown a positive correl-
ation between psoriasis disease severity and serum resistin lev-
els. There was some decrease in serum resistin after the
treatment but this was not significant (P = 0Æ1).
We also demonstrate that exogenous resistin can induce
monocytes to produce the inflammatory cytokines CXCL8 and
TNF-a in vitro (Fig. 4e,f) which is in agreement with Bokarewa
Fig 6. Evaluation of (a) leptin and (b) leptin receptor mRNA
expression levels in skin by quantitative real-time reverse transcriptase-
polymerase chain reaction. Leptin mRNA levels are of similar
magnitude in healthy, symptomless (uninvolved) psoriasis and lesional
psoriasis skin. However, leptin receptor mRNA expression is
significantly diminished in lesional psoriasis skin compared with both
healthy and symptomless skin. Mean (n = 13) ± SD, **P < 0Æ005,
two-tailed t-test.
Fig 7. Immunohistochemical evaluation of leptin receptor expression in (a) healthy skin, (b) uninvolved and (c) lesional psoriasis skin. Following
immunohistochemical detection of leptin receptor in skin biopsies from three healthy and three psoriatic donors the strength and extent of
receptor expression (red staining) was evaluated in the epidermal (d) and dermal (h) compartments using automated analysis with Image Pro
software. For comparison isotype control staining is also shown (e–g).
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et al.,43 who showed increases in IL-6 and TNF-a but not
IL-1b in the culture medium of PBMC cultures stimulated
with 1000 ng mL)1 resistin. Resistin has also been shown to
increase the expression by human endothelial cells of the vas-
cular cell adhesion molecule-1, CCL2 and endothelin-1.50 Res-
istin has furthermore been reported to promote proliferation
and migration of cultured endothelial cells and to increase the
expression of vascular endothelial growth factor receptors-1
and -2, and matrix metalloproteinases-1 and -2, culminating
in in vitro angiogenesis.51 Collectively these various activities of
resistin make it an attractive effector molecule in psoriasis.
Like resistin, leptin also induces the production of inflam-
matory cytokines by monocytes, and in addition to CXCL8
and TNF-a it also markedly induces the production of IL-1b
and IL-1ra (Fig. 4a–d). Further, using an ex vivo organotypic
culture system, we show that exogenously added leptin
induces psoriasis skin to produce amphiregulin, an ErbB1-
binding member of the EGF family that is known to drive
autocrine keratinocyte proliferation in culture,52 and to pro-
mote marked inflammatory hyperplasia when overexpressed in
the epidermis of transgenic mice. We also show that leptin
receptors are downregulated in lesional psoriasis skin while
they are constitutively expressed in healthy and uninvolved
psoriatic skin; thus leptin, like IL-23,53 may induce proinflam-
matory cytokine production from infiltrating lymphocytes
rather than acting directly on the keratinocytes themselves. It
is interesting in this context that leptin receptors have been
shown to be downregulated during early wound healing, and
then strongly expressed by mitotic keratinocytes at the wound
edge later in the healing process.54 Such differential regulation
of leptin-driven epidermal proliferation is impaired in
Lepob ⁄Lepob mice.55
CXCL8, a strong neutrophil chemoattractant, is also known
to stimulate the proliferation of keratinocytes.56 We report ele-
vated CXCL8 levels in the serum of patients with psoriasis and
that both resistin and leptin can induce the production of
CXCL8 by blood monocytes. Given that keratinocytes may both
respond to and secrete CXCL8, this chemokine is likely to con-
tribute to the keratinocyte hyperproliferation in psoriasis.
We can now perhaps begin to envision some links between
increases in the volume of adipose tissue and severity of psori-
asis. Thus, increased adiposity is associated with raised levels
of circulating cytokines, including leptin and resistin, which
may promote activation of T cells and monocytes, driving
both Th1 and Th17 immune responses and at the same time
impairing the function of regulatory T cells. High concentra-
tions of leptin may furthermore induce local production of
amphiregulin which, together with leptin- and resistin-stimu-
lated production of CXCL8, could help to drive the keratino-
cyte proliferation which is characteristic for psoriasis.
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